{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:6041",
      "entity_text" : "duration",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ01453",
      "entity_text" : "brentuximab vedotin",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "In a phase II trials of relapsed / refractory systemic ALCL cases, brentuximab vedotin therapy led to an overall response rate (ORR) and CR rate of 86% and 57%, respectively, with median CR duration of 13.2 months 6.",
  "reading_complete" : "2020-08-02T11:31:38Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T11:31:02Z",
  "trigger" : "led",
  "evidence" : [ "brentuximab vedotin therapy led to an overall response rate (ORR) and CR rate of 86% and 57%, respectively, with median CR duration" ],
  "pmc_id" : "5889253",
  "score" : 0
}